PUS3

Across TCGA pan-cancer cohorts, PUS3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PUS3 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PUS3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PUS3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where PUS3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.985	0.144	.002	57	view →
HNSC	DFS	Median	All	0.698	1.000	.031	16	view →
LSCC	DFS	Median	II,III,IV	0.915	0.636	.002	11	view →
GBM	DFS	Median	All	0.320	0.206	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PUS3–CCRCC (DFS)

Open the CCRCC breakdown →